µ²ºc¦¡ |
|
Dacomitinib
|
UpToDate |
UpToDate ³sµ²
|
ÃIJz§@¥Î |
|
Dacomitinib¬O¤@ºØ¥þ¤HÅéªí¥Ö¥Íªø¦]¼Æ¨üÅé¡]HER¡^¡]EGFR/HER1¡BHER2 ©M HER4¡^§í¨î¾¯¡A¦X¨Ö§Ü¬ðÅÜ EGFR ¥~¥[¥~Åã¤l19¯Ê¥¢©Î¥~Åã¤l 21¤§L858R¸m´«ªº§@¥Î¡CDacomitinib¿ï¾Ü©Ê¥B¤£¥i°f¦aµ²¦X¦Ü¨äHER®a±Ú¼Ð¹v¡A¥H´£¨Ñ§óªø®É¶¡ªº§í¨î¡C
|
¾AÀ³¯g |
|
°µ¬°³æ¤@Àøªk¡A¾A¥Î©ó±a¦³EGFR¬ðÅܤ§§½³¡±ß´Á©ÎÂಾ©Ê«D¤p²ÓMªÍÀù¡]NSCLC¡^¦¨¤H¯f¤Hªº²Ä¤@½uªvÀø¡C
|
¥Îªk¥Î¶q |
|
«Øij¾¯¶q¬°¨C¤é¤@¦¸¤fªA45²@§J¡Aª½¨ì¯e¯f´c¤Æ©Î¥X²{µLªk±µ¨üªº¬r©Ê¬°¤î¡CDacomitinib¥i¦ñÀH¹ª«©ÎªÅ¸¡ªA¥Î¡CÀ³ÁקK¦P®É¨Ö¥Î²BÂ÷¤lÀ°®ú§í¨î¾¯¡]PPI¡^»P dacomitinib¡C¥i¨Ï¥Î§½³¡§@¥Î«¬¨î»Ä¾¯¨ú¥N PPI¡A©ÎY¬O¨Ï¥Î²Õ´Ói²Ä2«¬¡]H2¡^¨üÅé«ú§Ü¾¯ªÌ¡A¦bªA¥ÎH2¨üÅé«ú§Ü¾¯«e¦Ü¤Ö2¤p®É©Î¨Ï¥Î«á10¤p®É¡A¦AªA¥Îdacomitinib¡C «Øij¯f¤H©ó¨C¤é¤j¬ù¦P¤@®É¶¡ªA¥Î¡CY¯f¤H¹Ã¦R©Îº|ªA¤@¾¯«h¤£À³ªA¥ÎÃB¥~¾¯¶q¡AÀ³¦b¹j¤Ñªº±`ºAªAÃĮɶ¡ªA¥Î¤U¤@Ó³B¤è¾¯¶q¡C
|
ÃİʤO¾Ç |
|
§l¦¬ ¬Û¸û©óÀR¯ßª`®g¡A¤fªA³æ¾¯45²@§Jdacomitinib¿õ¾¯«áªºµ´¹ï¥ÍÅé¥i¥Î²v¥§¡¬°80%¡]½d³ò¡G65%¦Ü100%¡^¡ACmaxµo¥Í©ó¤fªAÃĪ««á5¨ì6¤p®É¡C¨C¤éªA¥Îdacomitinib 45²@§J«á¡A¦b14¤Ñ¤º·|¹F¨ìéwª¬ºA¡C¹ª«¹ï¥ÍÅé¥i¥Î²vªº§ïÅÜ´T«×¤£¨ã¦³Á{§É·N¸q¡CDacomitinib¥i¦ñÀH¹ª«©ÎªÅ¸¡¨Ï¥Î¡CDacomitinib¬O¤@ºØ½¤¹B¿é³J¥ÕP‑ÁÞ³J¥Õ¡]P-gp¡^©M¨ÅÀù§ÜÃĩʳJ¥Õ¡]BCRP¡^ªº¨ü½è¡CµM¦Ó°ò©ó¨ä80%ªº¤fªA¥ÍÅé¥i¥Î²v¡A³o¨Ç½¤¹B¿é³J¥Õ¤£¤Ó¥i¯à¹ïdacomitinibªº§l¦¬²£¥Í¼vÅT¡C ¤À§G ¦bÀR¯ßµ¹ÃÄ«á¡Adacomitinib·|¥H27 L/kg¡]70¤½¤ç¯f¤H¡^¡]CV%¡G18%¡^ªº¥§¡Ã©wª¬ºA¤À§GÅé¿n¼sªx¤À§G¨ì¥þ¨¡C¦b¦å¼ß¤¤¡Adacomitinib·|µ²¦X¦Ü¥Õ³J¥Õ©MƒÑ1-»ÄÁÞ³J¥Õ¡A¥B¦bÅé¥~¤ÎÂ÷Åé°·±d¦ÛÄ@ªÌ¦å¼ß¤¤ªº¥¼µ²¦X¤ñ²v¬ù¬°2%¡C ¥Íª«Âà¤Æ ¦b¤HÅ餺¡Adacomitinib·|¶i¦æ®ñ¤Æ¤Î¨¦¯Ö¥Ì肽µ²¦X§@¥Î§@¬°¥Dn¥NÁ³~®|¡C¦b¤fªA³æ¾¯45²@§Jªº [14C] dacomitinib«á¡A³Ì¤j¶qªº´`Àô¥NÁª«¬°O-desmethyl dacomitinib¡C³o¶µ¥NÁª«¦bÅé¥~®i²{¥X»Pdacomitinib¬Û¦üªºÃIJz¾Ç¬¡©Ê¡C¦bÁT«K¤¤¡Adacomitinib¡BO-desmethyl dacomitinib¡Bµ²¦X¥b¯Ö®ò»Äªºdacomitinib ©Mdacomitinib ³æ®ñ¤Æ¥NÁª«¬O¥DnªºÃĪ«¬ÛÃö¦¨¤À¡CÅé¥~¸ÕÅç«ü¥XCYP2D6 ¬O§Î¦¨O-desmethyl dacomitinibªº¥DnCYP¦P¥\酶¡A¦ÓCYP3A4 «h¬Ot³d§Î¦¨¨ä¥L¦¸n®ñ¤Æ¥NÁª«¡CO‑desmethyl dacomitinib ¥e¤F¤HÅé¦å¼ß¤¤16% ªº©ñ®g¬¡©Ê¥B¥Dn¬O¥ÑCYP2D6 ¤Î¸û¤Ö³¡¤ÀªºCYP2C9 ¥NÁ§Φ¨¡C§í¨îCYP2D6 ·|ÂàÅܦ¨¥NÁª«¼ÉÅS¶q´î¤Ö¬ù 90% ¥H¤Îdacomitinib ¼ÉÅS¶q¼W¥[¬ù37%¡C
|
°Æ§@¥Î |
|
¸¡Âm¡B¥Ö¯l¡B¤fµÄª¢¡C
|
¥æ¤¬§@¥Î |
|
¨ÖªAdacomitinib»P¼W¥[G pH ȪºÃĪ« Dacomitinibªº¤ô¤¤·»¸Ñ«×¨ú¨M©ó pH È¡A§C pH È¡]»Ä©Ê¡^·|³y¦¨·»¸Ñ«×¸û°ª¡C¨Ó¦Û°·±d¨ü¸ÕªÌªº¸ÕÅç¼Æ¾Ú«ü¥X¨ÖªA³æ¾¯45 ²@§Jdacomitinib»P¦h¾¯PPI rabeprazole 40²@§J¤@¤Ñ¤@¦¸¡A¬Û¸û©ó¥uªA¥Î³æ¾¯ 45 ²@§JdacomitinibªÌ¡AdacomitinibªºCmax »PAUC0-96h ¡]¤¶©ó0¨ì96¤p®É¤§¿@«×®É¶¡¦±½u¤U±¿n¡^¤À§O·|¤U°¬ù51% ©M 39%¡C¦bdacomitinibªvÀø´Á¶¡À³ÁקK¨Ï¥Î PPI¡C
|
¸T§Ò |
|
°w¹ï¬¡©Ê¦¨¤À©Î¥é³æ¤¤©Ò¦Cªº¥ô¦ó½á«¬¾¯¹L±ÓªÌ¡C
|
µ¹¥I³W©w |
|
9.83.Dacomitinib (¦pVizimpro)¡G(109/10/1¡B111/9/1) 1.³æ¿W¨Ï¥Î¨ã¦³EGFR-TK Exon 19 Del©ÎExon 21 L858RÂI¬ðÅÜ¡A¥BµL¸£Âಾ (non-CNS)¤§§½³¡«I¥Ç©Ê©ÎÂಾ©Ê(§Y²Ä¢»B¡B¢»C©Î²Ä¢¼´Á)¤§ªÍ¸¢Àù¯f±w¤§²Ä¤@½uªvÀø¡A»ÝÀ˪þ¨Ì¥þ¥Á°·±d«OÀIÂåÀøªA°Èµ¹¥I¶µ¥Ø¤Î¤ä¥I¼Ð·Ç¦ñÀH¦¡¶EÂ_½s¸¹30101B©Î30102B³W©w¤§»{ÃÒ¹êÅç«Ç¥HÅé¥~¶EÂ_ÂåÀø¾¹§÷ÀË´ú¡]IVD¡^©Î¹êÅç«Ç¦Û¦æ¬ãµoÀË´ú(LDT)ÀËÅ礧EGFR°ò¦]ÀË´úµ²ªG³ø§i¡C 2.¨Ï¥Îª`·N¨Æ¶µ (1)¯f¾úÀ³¯d¦s½T¹ê±w¦³ªÍ¸¢Àù¤§¯f²z©Î²ÓMÀˬd³ø§i¡A¤ÎEGFR-TK°ò¦]¬ðÅÜÀË´ú³ø§i¡C (2)¨C¦¸³B¤è¥H4¶g¬°¡A¦A¦¸³B¤è®É»Ý©ó¯f¾ú°O¿ýªvÀø«á¬ÛÃöÁ{§É¸ê®Æ¡A¦p¨C4¶g»Ý°lÂܯݳ¡X¥ú©Î¹q¸£Â_¼hµ¥¼v¹³Àˬd¡A¨C8¦Ü12¶g»Ý¶i¦æ§¹¾ãÀø®Äµû¦ô¡]¦p¯Ý³¡X¥ú©Î¹q¸£Â_¼h¡^¡C (3)¥»ÃÄ«~»Pgefitinib¡Berlotinib¤Îafatinib¡A¶È±o¾Ü¤@¨Ï¥Î¡A°£¦]@¨ü©Ê¤£¨}¡A¤£±o¤¬´«¡C¦p»Ý§ó´«¨Ï¥Î¥»ÃÄ«~¡A¥²¶·²Å¦X¥»ÃÄ«~²Ä¤@½u¨Ï¥Î©ó¨ã¦³EGFR-TK Exon 19 Del©ÎExon 21 L858RÂI¬ðÅÜ¡A¥BµL¸£Âಾ(non-CNS)¤§§½³¡«I¥Ç©Ê©ÎÂಾ©Ê(§Y²Ä¢»B¡B¢»C©Î²Ä¢¼´Á)ªÍ ¸¢Àù¤§¨î¡C(111/9/1) (4)¨C¤é¥Î1²É¡C
|
ª`·N¨Æ¶µ |
|
1. À³¦bº¦¸¥X²{¸¡Âm¼x¥ü®É¡]¯S§O¬O¦b¶}©l dacomitinib ªvÀøªº«e¨â¶g¤º¡^¡Aµ¹¤©¹w¨¾©Ê³B¸m¡A¥]§t¨¬°÷ªº¤ô¤À¨Ö¥Î§Ü¸¡ÂmÃÄ«~¡A¥Bª½¨ìµ}³n«K®ø¥¢12¤p®É¬°¤î¡CÀ³¨Ï¥Î§Ü¸¡ÂmÃÄ«~¡]¦p loperamide¡^¡A¥B¥²n®É¼W¥[¦Ü³Ì°ª«Øij®Ö㾯¶q¡C¯f¤H¥i¯à»Ýn¤¤Â_¥ÎÃĤÎ/©Î°§Cdacomitinib¾¯¶q¡C¯f¤HÀ³ºû«ù¨¬°÷ªº¤ô¤ÀÄá¨ú¥B²æ¤ôªº¯f¤H¥i¯à»Ýn±µ¨üÀR¯ß¿é²G»P¹q¸Ñ½è¡C 2. ¥»ÃÄ«~§t¦³¨Å¿}¡C±w¦³¥b¨Å¿}¤£@¯g¡B¥þ¨Å¿}酶¯Ê¥F¯g¡A©Î¸²µå¿}-¥b¨Å¿}§l¦¬¤£¨}µ¥¨u¨£¿ò¶Ç¯fªº¯f¤H¡A¤£±o¨Ï¥Î¥»ÃÄ«~¡C 3. Vizimpro¹ï©ó¾r¾p¤Î¾Þ§@¾÷±ñ¯à¤O·|³y¦¨¨Ç·L¼vÅT¡C¦b¨Ï¥Îdacomitinib®Éµo¥Í¯h³Ò©Î²´³¡¤£¨}¤ÏÀ³ªº¯f¤H¦b¾r¾p©Î¾Þ§@¾÷±ñ®ÉÀ³ÂÔ·V¡C
|
¹L¶q³B²z |
|
¦b¾¯¶q¶W¹L¨C¤é¤@¦¸45²@§JªÌ¨¤WÆ[¹î¨ìªº¤£¨}¤ÏÀ³¥Dn¬OG¸z¹D¡B¥Ö½§©M¥þ¨©Ê¡]¦p¯h¡B¤£¾A¤ÎÅé«´î»´¡^¡C
Dacomitinib¨S¦³¤wª¾ªº¸Ñ¬r¾¯¡CDacomitinib¹L¶qªºªvÀøÀ³¥]¬A¯gª¬ªvÀø¤Î¥þ±©Ê¤ä«ù±¹¬I¡C
|
ÃÄ«~«O¦s¤è¦¡ |
|
½ÐÀx¦s©ó30ºC¥H¤U¡C
|